Diagnosis and Management of Cutaneous B-Cell Lymphomas

Stephen J Malachowski; James Sun; Pei-Ling Chen; Lucia Seminario-Vidal

doi:10.1016/j.det.2019.05.004

Diagnosis and Management of Cutaneous B-Cell Lymphomas

Dermatol Clin. 2019 Oct;37(4):443-454. doi: 10.1016/j.det.2019.05.004. Epub 2019 Jul 30.

Authors

Stephen J Malachowski¹, James Sun², Pei-Ling Chen², Lucia Seminario-Vidal³

Affiliations

¹ Department of Dermatology and Cutaneous Surgery, University of South Florida Morsani College of Medicine, 12901 Bruce B Downs Boulevard, Tampa, FL 33612, USA.
² Department of Cutaneous Oncology, Moffitt Cancer Center, 10920 McKinley Drive, Tampa, FL 33612, USA.
³ Department of Dermatology and Cutaneous Surgery, University of South Florida Morsani College of Medicine, 12901 Bruce B Downs Boulevard, Tampa, FL 33612, USA; Department of Cutaneous Oncology, Moffitt Cancer Center, 10920 McKinley Drive, Tampa, FL 33612, USA. Electronic address: [email protected].

PMID: 31466585
DOI: 10.1016/j.det.2019.05.004

Abstract

Primary cutaneous B-cell lymphomas are a group of diseases with indolent and aggressive behavior. The goal of the initial workup is to evaluate for systemic involvement, provide adequate staging, and guide therapy. Histopathological studies are a critical part of the workup for classification of these lymphomas because they are similar to their nodal counterparts. There are limited data for treatment guidelines, and thus, therapy differs among institutions. Overall, localized therapies are preferred for indolent types and chemotherapy or immunotherapy for the aggressive forms.

Keywords: B-cell lymphoma; Cutaneous diffuse large B-cell lymphoma; Cutaneous follicle center lymphoma; Cutaneous marginal zone lymphoma; Intravascular diffuse large B-cell lymphoma.

Publication types

Review

MeSH terms

Administration, Cutaneous
Adrenal Cortex Hormones / therapeutic use
Anti-Bacterial Agents / therapeutic use
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bexarotene / therapeutic use
Borrelia burgdorferi
Cyclophosphamide / therapeutic use
Cytoreduction Surgical Procedures
Dermatologic Surgical Procedures*
Disease Management
Doxorubicin / analogs & derivatives
Doxorubicin / therapeutic use
Humans
Injections, Intralesional
Lyme Disease / drug therapy
Lymphoma, B-Cell / diagnosis
Lymphoma, B-Cell / pathology
Lymphoma, B-Cell / therapy*
Lymphoma, B-Cell, Marginal Zone / diagnosis
Lymphoma, B-Cell, Marginal Zone / microbiology
Lymphoma, B-Cell, Marginal Zone / pathology
Lymphoma, B-Cell, Marginal Zone / therapy
Lymphoma, Large B-Cell, Diffuse / diagnosis
Lymphoma, Large B-Cell, Diffuse / pathology
Lymphoma, Large B-Cell, Diffuse / therapy
Mechlorethamine / therapeutic use
Polyethylene Glycols / therapeutic use
Prednisone / therapeutic use
Rituximab / therapeutic use
Skin Neoplasms / diagnosis
Skin Neoplasms / pathology
Skin Neoplasms / therapy*
Vincristine / therapeutic use

Substances

Adrenal Cortex Hormones
Anti-Bacterial Agents
Antineoplastic Agents
R-CHOP protocol
liposomal doxorubicin
Polyethylene Glycols
Rituximab
Mechlorethamine
Vincristine
Doxorubicin
Cyclophosphamide
Bexarotene
Prednisone